Loading
Adding a TIGIT blocker to PD-1/PD-L1 blockade looked good in phase 2 and then failed repeatedly in phase 3.
This caution pairing concerns adding a TIGIT blocker to Immune checkpoint inhibitors against PD-1 or PD-L1, a combination that looked promising in phase 2 and then failed repeatedly in phase 3. SKYSCRAPER-01 (Tiragolumab plus atezolizumab in Non-small-cell lung cancer), SKYSCRAPER-02 in Small-cell lung cancer and other trials were negative, the phase 2 signals did not reproduce, and Roche and others discontinued most TIGIT programmes in 2024-25. The reason for failure is unclear: Fc-effector requirements, patient selection and redundancy with PD-1 are the proposed explanations. The episode is cited in the idea that no accelerated approval should be granted for a combination without proof that each part contributes, and it is linked from the Tiragolumab and TIGIT entries.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares TIGIT, PD-L1, Non-small-cell lung cancer.
Shares TIGIT, Tiragolumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares TIGIT, Tiragolumab.
Shares TIGIT, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Tiragolumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/